IQVIA (NYSE:IQV) Downgraded to “Hold” Rating by StockNews.com

IQVIA (NYSE:IQV) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Thursday.

A number of other analysts have also issued reports on the stock. Morgan Stanley decreased their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Barclays decreased their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Truist Financial decreased their target price on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Finally, Evercore ISI decreased their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Up 0.1 %

IQV stock opened at $201.44 on Thursday. The company’s 50 day simple moving average is $220.36 and its 200-day simple moving average is $226.57. The firm has a market capitalization of $36.56 billion, a PE ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Hedge Funds Weigh In On IQVIA

Hedge funds have recently made changes to their positions in the business. PGGM Investments raised its stake in shares of IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares during the period. Simplify Asset Management Inc. increased its stake in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the period. Raymond James & Associates increased its stake in IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after buying an additional 5,417 shares during the period. Versor Investments LP purchased a new stake in IQVIA during the 3rd quarter worth $1,328,000. Finally, Gradient Investments LLC increased its stake in IQVIA by 15.6% during the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after buying an additional 6,134 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.